Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Congress 2022 | Oxygen-sensing mechanisms and erythrocytosis

Josef Prchal • 24 Nov 2022
MPN Congress 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Josef Prchal, MD, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, gives a presentation on oxygen-sensing mechanisms and erythrocytosis at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

More from Josef Prchal

Oxygen-sensing mechanisms and erythrocytosis 11:00
Oxygen-sensing mechanisms and erythrocytosis
Josef Prchal • 24 Oct 2022
Novel mutations in PV & the importance of understanding their role in disease initiation 1:35
Novel mutations in PV & the importance of understanding their role in disease initiation
Josef Prchal • 24 Oct 2022
A study of dizygotic twins with JAK2-positive MPNs 2:03
A study of dizygotic twins with JAK2-positive MPNs
Josef Prchal • 24 Oct 2022
The association between obstructive sleep apnea, inflammation and polycythemia vera 3:00
The association between obstructive sleep apnea, inflammation and polycythemia vera
Josef Prchal • 24 Oct 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals